News

7. January 2025

First patient dosed with NG004 in Phase 1b trial for acute spinal cord injury

NovaGo announces initiation of the SPROUT Phase 1b study of NG004 — the company’s transition to a clinical-stage company with its first asset.

19. December 2024

Phase 2 study of NG101 for acute spinal cord injury published in The Lancet Neurology

Results from the NISCI consortium’s placebo-controlled Phase 2 trial of an anti-Nogo-A antibody in 129 patients are published.

1. January 2024

Roger Wetli appointed Chief Financial Officer

NovaGo strengthens its management team as it intensifies outreach to investors.

1. November 2023

Dr. Stefan Moese appointed Chief Executive Officer

Founder Prof. Martin E. Schwab focuses on his role as Chief Scientific Officer and Chairman of the Board.